Michael Elliott, MD
Internal Medicine · Edmond, OKNPI 1770581803
Payments from drug & device makers
Across 381 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$969
- GSK$727
- AstraZeneca$670
- Novo Nordisk$527
- Lilly USA, LLC$492
- Takeda Pharmaceuticals U.S.A., Inc.$425
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,684100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 67 | $969 |
| GSK | 60 | $727 |
| AstraZeneca(2 entities) | 45 | $670 |
| Novo Nordisk | 36 | $527 |
| Lilly USA, LLC | 37 | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $425 |
| Merck | 21 | $289 |
| Boehringer Ingelheim | 19 | $278 |
| Sumitomo Pharma America, Inc. | 8 | $184 |
| AbbVie(2 entities) | 10 | $159 |
| Shire North American Group Inc | 9 | $146 |
| Amgen(2 entities) | 6 | $105 |
| Sanofi-aventis U.S. LLC | 7 | $105 |
| Sanofi Pasteur Inc. | 4 | $70 |
| Abbott | 4 | $67 |
| Genentech USA, Inc. | 4 | $63 |
| Bayer | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Exact Sciences | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $26 |
| Currax Pharmaceuticals LLC | 2 | $25 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $14 |
| Almatica Pharma LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Eisai Inc. | 1 | $11 |
How this compares
$5,684 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 100 | $111,770 |
| JardianceEmpagliflozin | 91 | $103,822 |
| OzempicSemaglutide | 54 | $78,975 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $73,568 |
| TrulicityDulaglutide | 30 | $56,611 |
| MounjaroTirzepatide | 26 | $50,630 |
| RybelsusSemaglutide | 16 | $29,690 |
| XareltoRivaroxaban | 24 | $25,000 |
| FarxigaDapagliflozin Propanediol | 23 | $19,914 |
| MyrbetriqMirabegron | 11 | $12,209 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $11,699 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,287 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $7,035 |
| Atorvastatin Calcium | 425 | $5,410 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $4,435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $969 | $111,770100 claims |
| Novo NordiskOzempic, Rybelsus | $527 | $108,66570 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $492 | $107,24156 claims |
| Boehringer IngelheimJardiance | $278 | $103,82291 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $727 | $83,85573 claims |
| Johnson & JohnsonXarelto | $26 | $25,00024 claims |
| AstraZenecaFarxiga | $670 | $19,91423 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $12,20911 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $1,21780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Edmond
- Todd KrehbielEdmond$21K
- Ashlee WaughEdmond$15K
- William MorganEdmond$13K
- Thomas KupiecEdmond$12K
- Al-Ola AbdallahTulsa$10.1M
- Melita TateTulsa$9.1M
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Renae MayerTulsa$766K
- George FreemanIdabel$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.